CoChat

Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma

Kaufman, Jonathan L., Niesvizky, Ruben, Stadtmauer, Edward A., Chanan‐Khan, Asher, Siegel, David, Horne, Heather, Wegener, William A., Goldenberg, David M. · 2013 · British Journal of Haematology
Cited by 125

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Summary: CD 74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti‐CD 74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short‐lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute‐Common Terminology Criteria v3 toxicity Grades 1–2) with no dose‐limiting toxicity at higher doses. Only one patient developed borderline positive human anti‐milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B‐cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post‐treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.12565

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 125

Metadata

Authors
Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan‐Khan, A., Siegel, D., Horne, H., Wegener, W. A., & Goldenberg, D. M.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2013-09-25
Volume
163
Issue
4
Pages
478-486
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2017357058
Cited by
125
References
6
FWCI
6.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma. https://app.cochat.ai/papers/10.1111/bjh.12565
The paper
Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan‐Khan, A., Siegel, D., Horne, H., Wegener, W. A., & Goldenberg, D. M. (2013). Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.12565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.